Credit Suisse’s GenMark Diagnostics, Inc GNMK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q2 | – | Sell |
-251,541
| Closed | -$6.01M | – | 4762 |
|
|
2021
Q1 | $6.01M | Buy |
251,541
+168,778
| +204% | +$3.14M | ﹤0.01% | 1928 |
|
|
2020
Q4 | $1.21M | Buy |
82,763
+27,878
| +51% | +$370K | ﹤0.01% | 3197 |
|
|
2020
Q3 | $780K | Sell |
54,885
-4,126
| -7% | -$63K | ﹤0.01% | 3114 |
|
|
2020
Q2 | $868K | Buy |
59,011
+31,464
| +114% | +$320K | ﹤0.01% | 2986 |
|
|
2020
Q1 | $114K | Sell |
27,547
-1,882
| -6% | -$8.82K | ﹤0.01% | 3794 |
|
|
2019
Q4 | $141K | Sell |
29,429
-12,363
| -30% | -$68.2K | ﹤0.01% | 4040 |
|
|
2019
Q3 | $253K | Buy |
41,792
+2,852
| +7% | +$17.8K | ﹤0.01% | 3773 |
|
|
2019
Q2 | $252K | Sell |
38,940
-6,758
| -15% | -$47.6K | ﹤0.01% | 3762 |
|
|
2019
Q1 | $324K | Buy |
45,698
+13,314
| +41% | +$87.7K | ﹤0.01% | 3564 |
|
|
2018
Q4 | $156K | Sell |
32,384
-164
| -0.5% | -$854 | ﹤0.01% | 3712 |
|
|
2018
Q3 | $240K | Sell |
32,548
-10,268
| -24% | -$75.3K | ﹤0.01% | 3606 |
|
|
2018
Q2 | $273K | Sell |
42,816
-2,271
| -5% | -$15K | ﹤0.01% | 3661 |
|
|
2018
Q1 | $246K | Buy |
45,087
+17,667
| +64% | +$87.8K | ﹤0.01% | 3643 |
|
|
2017
Q4 | $114K | Sell |
27,420
-30,810
| -53% | -$185K | ﹤0.01% | 3824 |
|
|
2017
Q3 | $561K | Buy |
58,230
+31,698
| +119% | +$329K | ﹤0.01% | 3476 |
|
|
2017
Q2 | $313K | Buy |
26,532
+4,129
| +18% | +$52.8K | ﹤0.01% | 3438 |
|
|
2017
Q1 | $288K | Sell |
22,403
-12,274
| -35% | -$148K | ﹤0.01% | 3526 |
|
|
2016
Q4 | $424K | Sell |
34,677
-60,154
| -63% | -$714K | ﹤0.01% | 3523 |
|
|
2016
Q3 | $1.12M | Buy |
94,831
+57,797
| +156% | +$558K | ﹤0.01% | 2857 |
|
|
2016
Q2 | $322K | Buy |
37,034
+14,012
| +61% | +$96.1K | ﹤0.01% | 3667 |
|
|
2016
Q1 | $122K | Sell |
23,022
-5,322
| -19% | -$29.6K | ﹤0.01% | 3791 |
|
|
2015
Q4 | $221K | Sell |
28,344
-9,443
| -25% | -$72.5K | ﹤0.01% | 3835 |
|
|
2015
Q3 | $297K | Buy |
37,787
+611
| +2% | +$5.65K | ﹤0.01% | 3722 |
|
|
2015
Q2 | $337K | Buy |
37,176
+4,654
| +14% | +$46.9K | ﹤0.01% | 3962 |
|
|
2015
Q1 | $422K | Buy |
32,522
+12,934
| +66% | +$169K | ﹤0.01% | 3656 |
|
|
2014
Q4 | $267K | Sell |
19,588
-18,978
| -49% | -$212K | ﹤0.01% | 4129 |
|
|
2014
Q3 | $346K | Buy |
38,566
+9,155
| +31% | +$98.5K | ﹤0.01% | 3859 |
|
|
2014
Q2 | $398K | Buy |
29,411
+6,600
| +29% | +$68.9K | ﹤0.01% | 3960 |
|
|
2014
Q1 | $227K | Buy |
22,811
+2,492
| +12% | +$31K | ﹤0.01% | 4286 |
|
|
2013
Q4 | $271K | Buy |
20,319
+4,067
| +25% | +$49.4K | ﹤0.01% | 4150 |
|
|
2013
Q3 | $197K | Sell |
16,252
-58,443
| -78% | -$627K | ﹤0.01% | 3970 |
|
|
2013
Q2 | $773K | Buy |
+74,695
| New | +$1.03M | ﹤0.01% | 2994 |
|
Credit Suisse's GNMK Position: Q2 2021 in Review
Credit Suisse sold out of GenMark Diagnostics, Inc (GNMK) in Q2 2021, closing a stake of 251,541 shares — an estimated $6.01M sold.
Credit Suisse first reported a position in GNMK in Q2 2013 and held it in 32 quarters. The position peaked at $6.01M in Q1 2021. 0 funds tracked by Wall St. Rank hold GNMK as of Q2 2021.
- Credit Suisse reported no remaining GenMark Diagnostics, Inc position as of Q2 2021 after selling out during the quarter.
- Credit Suisse sold 251,541 GenMark Diagnostics, Inc shares in Q2 2021, an estimated $6.01M.
- Credit Suisse first reported a position in GenMark Diagnostics, Inc in Q2 2013 and held it in 32 quarters.
- Credit Suisse's GenMark Diagnostics, Inc position peaked at $6.01M in Q1 2021.
- 0 funds tracked by Wall St. Rank held GenMark Diagnostics, Inc as of Q2 2021.
Based on Credit Suisse's 13F filing for Q2 2021, filed 16 Aug 2021.